Condition
Ulcerative colitis news across medications, symptoms, monitoring, procedures, research, access, and daily life.
Page 3 of 40 · 1908 articles
This study uses transcriptomics, single‑cell data, and machine learning to nominate lactylation‑related genes as biomarkers and drug targets in ulcerative colitis, which could guide future biomarker or drug‑repurposing...
The study explores whether people with UC in deep histologic remission can reduce or stop maintenance medications without losing remission — a question many patients and clinicians face because of medication costs, side...
A combo that adds an α4β7 blocker to an IL-23 inhibitor showed higher endoscopic remission at Week 12 than either drug alone in a phase 2 Crohn’s trial, which could point to a new treatment strategy for people who’ve...
This review summarizes how ulcerative colitis trials have been designed recently and flags common weaknesses (small samples, short follow-up, overreliance on Mayo score). Better-designed trials could produce results that...
If validated, antibody signatures could enable earlier identification of people at higher risk of developing IBD and help predict which patients may develop more severe disease, creating opportunities for earlier...
If validated, antibody-based signatures could enable much earlier detection of IBD and help identify people at risk of more severe Crohn’s disease years before symptoms—potentially opening opportunities for research on...
If validated, blood antibody patterns could allow earlier identification of people at risk for Crohn’s disease or ulcerative colitis — potentially before bowel damage occurs — opening opportunities for earlier monitoring...
Based on the title and source metadata, this appears to be a guideline related to Ulcerative colitis, Inflammatory bowel disease, and Colectomy. The original article is from Techniques in Coloproctology.
The study suggests people with IBD consumed more dietary emulsifiers than healthy controls and found initial links between higher UPF/emulsifier intake and worse IBD-related events, which could be important if diet...
Children with IBD can present differently than adults and may show early signs outside the gut. The special-issue papers highlight improved, less-invasive diagnostic tools and increasing use of targeted biologic...
Longer-term and real-world data help patients and clinicians understand how well risankizumab and upadacitinib maintain clinical and endoscopic improvement over years of treatment, and early data on an investigational...
Preclinical evidence that a natural compound (Fraxin) can reduce epithelial necrosis and inflammation in UC models points to a potential new target (P2Y14R/cAMP/PKA/CREB) for future drug research and possibly novel...
Researchers and clinicians want biomarkers that predict outcome or tailor treatment. This study suggests a mucosal gene-expression score is prognostic and declines in responders, but it does not yet show the score...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Medications. The original article is from Journal of Visualized Experiments.
Lifestyle factors like diet, exercise, and mental‑health support may help people with ulcerative colitis, but delivering them together is complex.
Vitamin D deficiency was very common in this IBD cohort and was linked to Crohn’s disease and female sex, which may matter because deficiency can affect bone health and immune regulation in people with IBD.
For people hospitalized with acute severe UC, the findings suggest that measuring early infliximab pharmacokinetics could help personalize rescue therapy and potentially reduce colectomy risk by identifying who may need...
Based on the title and source metadata, this appears to be an opinion or commentary related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Translational...
Understanding microbiota–neuroimmune interactions could explain why symptoms like urgency and pain persist in some people with UC and may point to new treatment strategies that go beyond conventional anti-inflammatory...
Based on the title and source metadata, this appears to be an opinion or commentary related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Translational gastroenterology...
Based on the title and source metadata, this appears to be an opinion or commentary related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from Translational...
The findings suggest that tissue-based immune profiling may better identify biologically distinct subgroups in ulcerative colitis than blood tests, which could affect research on personalized treatment or trial...
If replicated and confirmed, the genetic evidence that shorter telomeres increase risk of fibrotic lung disease (IPF) helps clarify that telomere length itself — not just telomerase-pathway genes — may be relevant to...
This study suggests a plant extract (Macleaya cordata) and its component sanguinarine reduced inflammation and improved colitis signs in mice by changing gut bacteria and macrophage activation — mechanisms relevant to...
This study aims to show how mirikizumab and other biologics perform in everyday community practice — information that can help clinicians and patients understand real-world treatment durability, symptom control, and...
This study aims to measure how much time people with ulcerative colitis spend with objectively uncontrolled inflammation and to compare real-world outcomes of different initial advanced-therapy choices and...
The study links an experimental treatment (dexpanthenol) to reduced inflammatory cytokines and improved anxiety-like behaviors in a rat colitis model, which is relevant to research on inflammation-driven gut–brain...
If reliable, blood biomarkers that track IBD activity could help noninvasively follow children with Crohn’s disease or ulcerative colitis. This study suggests MMP-9 and TIMP-1 change with disease course but did not show...
The work suggests new molecular readouts (fecal metaproteomics and lysine crotonylation) that could help explain why some people with ulcerative colitis respond to FMT while others do not, potentially guiding future...
The trial tests a naturally derived oral supplement (WPMDE2) in patients with ulcerative colitis, measuring symptoms, inflammatory markers, and quality of life—outcomes that matter to people living with IBD. Early-phase...
A registry focused on "difficult-to-treat" IBD aims to describe how often and why patients become treatment-refractory, how their disease and treatments evolve over time, and which outcomes (hospitalization, surgery,...
Cardiovascular disease is an important extraintestinal concern for people with IBD, and current risk scores may miss IBD-specific drivers. This study aims to track heart and vascular events in IBD and find biomarkers...
This early-phase trial explores a novel, targeted bacteriophage treatment for pouchitis linked to an Aeromonas-associated pathogen (MTB). For people with pouchitis after IPAA, a safe, effective phage therapy could...
People with Crohn’s disease or ulcerative colitis may have higher cardiovascular risk; this prospective study aims to measure how often major heart and vascular events occur in IBD and to find biological and clinical...
Patients with IBD have an increased colorectal cancer risk, and those with PSC, extensive colitis, severe inflammation, or prior dysplasia are at especially high risk. High-quality surveillance techniques can improve...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Remission, and Research and clinical trials. The original article is from Inflammatory Bowel Diseases.
Real-world data on upadacitinib help patients and clinicians understand how the drug performs outside clinical trials, including how long patients stay on treatment, remission rates, and common side effects.
The report suggests fertility treatments—particularly embryo transfer/IVF—can be successful for many women with Crohn's disease or ulcerative colitis, which may reassure patients concerned about fertility after IBD or...
This preclinical work suggests the gut microbiota and tryptophan-derived metabolites that activate AhR may be important in reducing colitis-related inflammation — a potential route for future therapies relevant to...
Company-reported one-year results suggest mirikizumab (Omvoh), an IL-23p19 inhibitor, can achieve multi-dimensional treatment goals including symptom control, quality-of-life improvement, and steroid-free deep remission...
Support organizations can offer education, peer connection, mental-health services, advocacy, and programs for children and families that complement medical care. Knowing where to find these resources can help people...
An oral IL-23 blocker showed benefit in a Phase IIb trial for moderate-to-severe ulcerative colitis, which could add a new pill option for patients—especially those who’ve failed injectable biologics.
The article reports Phase 3 post‑hoc analyses showing that mirikizumab (Omvoh) produced higher rates of composite, multidimensional remission measures in UC and Crohn’s disease versus placebo, which could matter to...
Phase 3 results suggest mirikizumab (Omvoh) can produce sustained, steroid-free remission-related outcomes at one year in both ulcerative colitis and Crohn’s disease, including in some patients who previously failed...
Cure8 could only read part of this source from benzinga.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis and Research and clinical trials.
The study suggests a dietary protein (ovotransferrin) can reduce colitis severity in mice by changing the gut microbiota and increasing certain secondary bile acids that lower inflammation and gut permeability.
New one-year trial analyses suggest mirikizumab (Omvoh) may help more people with moderate-to-severe ulcerative colitis or Crohn’s disease reach combined clinical and endoscopic goals and reduce steroid dependence.
These results suggest mirikizumab can achieve multiple treatment goals at once — symptoms, objective inflammation measures, and steroid-free status — outcomes that matter to people with IBD because they reflect both...
